https://scholars.lib.ntu.edu.tw/handle/123456789/494538
標題: | PI3K inhibitor provides durable response in metastatic metaplastic carcinoma of the breast: A hidden gem in the BELLE-4 study | 作者: | MING-HAN YANG I-CHUN CHEN YEN-SHEN LU |
公開日期: | 2019 | 出版社: | Elsevier B.V. | 卷: | 118 | 期: | 9 | 起(迄)頁: | 1333-1338 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | Purpose: Metaplastic carcinoma of the breast (MCB) is a rare cancer characterized by the histologic presence of two or more histological cell types originating from epithelial and mesenchymal stem cells. Patients with metastatic MCB have a low response rate to conventional chemotherapy and poor survival. Optimal treatment strategies for metastatic MCB are urgently needed. Methods: We retrospectively reviewed a patient who had enrolled in the phase II/III seamless study, BELLE-4 (NCT01572727). The patient's response to the study drug assessed by an investigator per protocol and clinical course were examined and compared with those of the main cohorts in the BELLE-4 study. Results: Our patient exhibited metastatic MCB and received systemic chemotherapy, paclitaxel (70 mg/m2/week) and buparlisib (80 mg/day), a pan-class I phosphatidylinositol-3 kinase (PI3K) inhibitor. The optimal response was a confirmed partial response for 17 months in total. During the compassionated use program period, the tumor regrew when buparlisib was stop because of toxicity, and responded to the treatment again after resumed the buparlisib treatment. The overall survival of the patient after the development of metastatic MCB was 42 months. She experienced grade 3 hyperglycemia similar to that observed in the main cohort. Conclusion: Buparlisib plus weekly paclitaxel might be a new treatment option for patients with metastatic MCB harboring a PIK3CA mutation. Additional prospective studies for investigating the efficacy of the proposed combination are warranted. ? 2018 Formosan Medical Association |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85058569564&doi=10.1016%2fj.jfma.2018.12.004&partnerID=40&md5=ee29d416124e0956a228abcf864c80ae https://scholars.lib.ntu.edu.tw/handle/123456789/494538 |
ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2018.12.004 | SDG/關鍵字: | buparlisib; cyclophosphamide; cytokeratin; paclitaxel; UFT; vimentin; aminopyridine derivative; antineoplastic agent; morpholine derivative; NVP-BKM120; paclitaxel; adjuvant radiotherapy; aged; Article; cancer combination chemotherapy; cancer growth; cancer patient; case report; computer assisted tomography; contrast enhancement; drug withdrawal; female; human; human epidermal growth factor receptor 2 positive breast cancer; hyperglycemia; lung metastasis; major clinical study; metaplastic carcinoma; metastatic breast cancer; multiple cycle treatment; overall survival; phase 2 clinical trial (topic); phase 3 clinical trial (topic); progression free survival; randomized controlled trial (topic); retrospective study; simple mastectomy; systemic therapy; thorax radiography; treatment duration; treatment response; triple negative breast cancer; very elderly; breast tumor; carcinoma; metaplasia; pathology; treatment outcome; x-ray computed tomography; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Female; Humans; Metaplasia; Morpholines; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Randomized Controlled Trials as Topic; Tomography, X-Ray Computed; Treatment Outcome |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。